Regeneron Says Supreme Court Ruling Ends Patent Dispute With Amgen
18 Maio 2023 - 1:59PM
Dow Jones News
By Denny Jacob
Regeneron Pharmaceuticals on Thursday said a U.S. Supreme Court
opinion affirms a lower court opinion that held Amgen's asserted
U.S. PCSK9 patent claims were invalid.
Biotechnology company Regeneron said the Supreme Court's opinion
ends a nearly decade-long patent dispute related to its PCSK9
inhibitor, Praluent.
"We're gratified that the Supreme Court has affirmed the
position we have held for nearly ten years that Amgen's PCSK9
patents were overly broad and inconsistent with established case
law," said Executive Vice President Joseph LaRosa.
Amgen didn't immediately respond to a request for comment.
Write to Denny Jacob at denny.jacob@wsj.com
(END) Dow Jones Newswires
May 18, 2023 12:44 ET (16:44 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.
Amgen (NASDAQ:AMGN)
Gráfico Histórico do Ativo
De Mar 2024 até Abr 2024
Amgen (NASDAQ:AMGN)
Gráfico Histórico do Ativo
De Abr 2023 até Abr 2024